HOME HELP FEEDBACK SUBSCRIPTIONS ALL ISSUES SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frederick, B. deB. Articles by Renshaw, P. F. Search for Related Content PubMed PubMed Citation Articles by Frederick, B. deB. Articles by Renshaw, P. F.

Brain Proton Magnetic Resonance Spectroscopy in Alzheimer Disease

Changes After Treatment With Xanomeline

Received April 13, 2001; revised August 16, 2001; accepted August 20, 2001. From McLean Hospital Brain Imaging Center, Belmont, MA. Address correspondence to Dr. Frederick, McLean Hospital Brain Imaging Center, 115 Mill St., Belmont, MA 02478.

Patients with mild-to-moderate Alzheimer disease received transdermal xanomeline, an M₁-selective cholinergic agonist, or placebo for 4 months. Clinical assessments and proton magnetic resonance spectroscopic imaging examinations were carried out at baseline, and after 8 and 16 weeks of treatment. There was a positive correlation between change from baseline in parietal lobe gray-matter cytosolic choline, expressed in terms of choline/creatine resonance ratios, and cognitive performance as measured with the Alzheimer's Disease Assessment Scale Cognitive Subscale. Specifically, increased levels of cytosolic choline, a precursor pool for acetylcholine synthesis, were associated with greater progression in memory impairment during treatment.

Key Words: Alzheimer Disease • MRS • Xanomeline

This article has been cited by other articles:

				N. Kapur and M. D Kopelman Advanced brain imaging procedures and human memory disorder Br. Med. Bull., March 1, 2003; 65(1): 61 - 81. [Abstract] [Full Text] [PDF]

				Y.-H. Suh and F. Checler Amyloid Precursor Protein, Presenilins, and alpha -Synuclein: Molecular Pathogenesis and Pharmacological Applications in Alzheimer's Disease Pharmacol. Rev., September 1, 2002; 54(3): 469 - 525. [Abstract] [Full Text] [PDF]